Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Vericel Q1 2026 Earnings Call - Record Revenue Surge and BARDA Contract Fuel Growth
Vericel delivered a standout first quarter, with total revenue jumping 30% to $68.4 million, well above guidance, driven by a 22% surge in MACI sales and a 90% spike in Burn Care revenue. The company ...
- Total revenue hit a record $68.4 million in Q1 2026, up 30% year-over-year and significantly beating guidance.
- MACI revenue surged 22% to $56.4 million, driven by double-digit volume growth and an expanded sales force.
- Burn Care revenue jumped over 90% to $12 million, with Epicel and NexoBrid both contributing to the outperformance.
- +7 more takeaways
BlackSky Technology Q1 2026 Earnings Call - Gen-3 Satellites Drive Revenue and Margin Expansion
BlackSky Technology reported a strong start to 2026, with Q1 revenue of $20.8 million and a raised full-year outlook. The company's Gen-3 constellation, now at four operational satellites, is the prim...
- Q1 2026 revenue reached $20.8 million, up 14% sequentially, driven by the commercial ramp of the Gen-3 satellite constellation.
- Full-year revenue guidance was raised to $130-$150 million, reflecting a 30% midpoint growth rate over 2025.
- Adjusted EBITDA guidance was increased to $12-$24 million, targeting a 13% margin at the midpoint.
- +12 more takeaways
Diversified Energy Q1 2026 Earnings Call - $1.2B Off-Balance Sheet Acquisition via Carlyle SPV
Diversified Energy delivered a record Q1 2026 with adjusted EBITDA of $287 million and $160 million in adjusted free cash flow, while maintaining strict capital discipline. The highlight of the quarte...
- Diversified Energy announced a $1.175 billion acquisition of assets from Camino Natural Resources, partnered with Carlyle.
- The transaction is structured as an off-balance sheet SPV with equity method accounting, keeping ABS debt off Diversified's consolidated balance sheet.
- Diversified's total consideration is approximately $210 million, funded by existing liquidity with no equity issuance required.
- +12 more takeaways
Insmed Q1 2026 Earnings Call - BRINSUPRI Launch Exceeds Expectations, ARIKAYCE Label Expansion Looms
Insmed's BRINSUPRI launch is setting a new benchmark for specialty respiratory drugs, delivering 44% sequential growth and outpacing historical analogs despite the traditional headwinds of a calendar ...
- BRINSUPRI delivered 44% sequential growth in Q1 2026, outperforming historical respiratory launch analogs and defying typical calendar Q1 seasonality.
- Management estimates that approximately 5,000 of the initial patient starts were from a pre-launch pool of 70,000 'ready and waiting' patients, with organic demand now becoming the primary growth driver.
- Payer access remains robust, with a 90% approval rate for patients processed through specialty pharmacies and an average approval time of less than one week.
- +7 more takeaways
Peloton FY2026 Q3 Earnings Call - Revenue Growth and Strategic Optionality
Peloton delivered its first positive year-over-year revenue growth in fiscal 2026 Q3, reaching $631 million and beating guidance by $6 million. The company is actively pivoting from a connected fitnes...
- Q3 fiscal 2026 total revenue reached $631 million, marking the first positive year-over-year growth and beating guidance by $6 million.
- Free cash flow surged 59% year-over-year to $151 million, supported by disciplined cost management and strong subscription cash generation.
- Net debt plummeted 70% year-over-year to $173 million, leaving the company with a pristine $1.13 billion cash balance and near-zero leverage.
- +7 more takeaways
Stevanato Group Q1 2026 Earnings Call - GLP-1 Surge Fuels Biologics Growth While Engineering Segment Stalls
Stevanato Group delivered a strong first quarter in fiscal 2026, with revenue rising 10% on a constant currency basis to EUR 273.6 million, driven by a 13% jump in its Drug Delivery Solutions (BDS) se...
- Revenue grew 10% at constant currency to EUR 273.6 million, with the BDS segment up 13% and the Engineering segment down 31%.
- GLP-1 therapies now represent 21%-22% of total revenue, driving a 15% increase in biologics revenue, the company's fastest-growing end market.
- Demand for sterile cartridges is accelerating beyond expectations, with the company now fully booked on cartridge capacity through 2026.
- +12 more takeaways
Chicago Atlantic Real Estate Finance Inc. Q1 2026 Earnings Call - Cannabis Rescheduling Boosts Portfolio Outlook
Chicago Atlantic Real Estate Finance (REFI) reported stable Q1 2026 results, driven by a $482 million pipeline and strategic positioning in the cannabis sector. The company highlighted the recent fede...
- Federal rescheduling of medical marijuana to Schedule III marks a historic policy shift, expected to reduce Section 280E tax burdens and improve borrower cash flows.
- Pipeline stands at $482 million, with $133 million backed by real estate collateral, signaling strong deal flow in a niche market.
- Portfolio principal totaled $414 million across 25 companies, with a weighted average yield of 15.8% and 10.7% risk-rated 4 or higher.
- +7 more takeaways
Stoneridge Inc Q1 2026 Earnings Call - MirrorEye Revenue Hits Record $33M as Margins Expand Amid Weak Commercial Vehicle Markets
Stoneridge delivered a stronger-than-expected first quarter, driven by record MirrorEye sales of $33 million and a 400 basis point expansion in adjusted gross margin. The company outperformed its weig...
- Q1 2026 revenue grew 9.2% quarter-over-quarter to $160.8 million, outperforming the weighted average OEM end market which declined 9.1%.
- MirrorEye CMS achieved a record quarterly sales figure of $33 million, representing 11% sequential growth and 32% year-over-year growth.
- Adjusted gross margin expanded by 400 basis points compared to Q4 2025, driven by manufacturing productivity, quality cost reductions, and net tariff recoveries.
- +7 more takeaways
InfuSystem Holdings, Inc. Q1 2026 Earnings Call - ERP Go-Live and Wound Care Surge Drive Margin Expansion
InfuSystem Holdings delivered a quarter defined by transition and tactical wins rather than top-line growth. Pro forma revenue grew 1.7% as the company successfully navigated a contract restructuring ...
- Pro forma revenue grew 1.7% year over year, masking a 3% GAAP decline driven by a GE HealthCare contract restructuring that lowered revenue but improved margins.
- Wound care net revenue surged 112% to $2.1 million, now representing 6% of total revenue, with growth led by new pneumatic compression devices and adjustable compression wraps.
- Adjusted EBITDA held steady at $6.4 million, with the margin expanding to 18.9% from 18.2% a year ago as gross profit increased 3% despite lower sales.
- +9 more takeaways
CareCloud Q1 2026 Earnings Call - Capital Structure Simplification and AI Product Scaling
CareCloud delivered a solid Q1 2026 with 13% revenue growth to $31.3 million, driven by recurring revenue strength and the early integration of its 2025 acquisitions. The standout development is the f...
- Revenue grew 13% year-over-year to $31.3 million in Q1 2026, with recurring technology-enabled revenue rising to $23 million.
- Management executed a transformative capital structure simplification, closing a new $50 million credit facility and announcing the 100% redemption of Series B preferred stock to eliminate preferred equity overhang.
- The removal of preferred dividends and transition to senior debt lowers the weighted average cost of capital and broadens the potential investor base by simplifying the equity stack.
- +9 more takeaways